Welcome to the Starpharma investor centre.

Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform.

asx.jpg

View All
ASX Announcements

 

Need to update your
shareholder details

 

Download 
Annual Report

View the 
Analyst coverage

 

Have an
Investor query?

 

Register here
for email updates

Latest News & Announcements

Click here for news archive

Starpharma signs new DEP® agreement with MSD

Aug 10th, 2022

Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.

Read More

Quarterly Activities Report & Appendix 4C

Jul 29th, 2022

Starpharma today released its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2022. 

Read More

VIRALEZE™ relaunched by LloydsPharmacy in the UK (ASX Announcement)

Jun 30th, 2022

Starpharma today announced that VIRALEZE™ nasal spray has been relaunched by LloydsPharmacy in the UK. 

Read More

Shareholder Newsletter June 2022

Jun 3rd, 2022

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Newsletter June 2022 is now available to view online.

Read More

Reports & Presentations

Click here for financial reports archive

Quarterly Activities Report & Appendix 4C

Jul 29th, 2022

Starpharma today released its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2022. 

Read More

Quarterly Cashflow and Activities Report (ASX Announcement)

Apr 29th, 2022

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2022.

Read More

Quarterly Cashflow and Activities Report (ASX Announcement)

Jan 28th, 2022

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2021.

Read More

AGM Chairman’s address and CEO’s presentation (ASX Announcement)

Nov 30th, 2021

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

Read More

Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)

Nov 9th, 2021

Starpharma has been invited to present today at the exclusive virtual 2021 Bell Potter Healthcare Conference. The Bell Potter Healthcare Conference showcases leading companies within the Australian healthcare sector and brings together industry leaders with Bell Potter’s network of international and domestic investors, analysts and advisers. The event is available to live-stream via Bell Potter Client Access on 9 – 11 November.

Read More

Quarterly Cashflow and Activities Report (ASX Announcement)

Oct 29th, 2021

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2021.

Read More

Starpharma annual report and full year financial results (ASX Announcement)

Aug 26th, 2021

Starpharma today released its annual report and financial results for the year ended 30 June 2021.

 

Read More

Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)

Jun 24th, 2021

Starpharma today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as advisors.

Read More